Predicted protein targets (top 8)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR6 | P50406 | 18/20 | 0.68 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.51 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.51 |
| ▸ | HTR1A | P08908 | 1/20 | 0.51 |
| ▸ | DRD2 | P14416 | 1/20 | 0.51 |
| ▸ | HTR2A | P28223 | 1/20 | 0.51 |
| ▸ | HTR7 | P34969 | 1/20 | 0.51 |
| ▸ | DRD3 | P35462 | 2/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3378968 | 0.95 | HTR6 (0.62) | HTR6CHRNB2CHRNA4 | |
| SCHEMBL6488471 | 0.90 | CHRNB2 (0.58) | HTR6CHRNB2CHRNA4 | |
| SCHEMBL3377181 | 0.89 | HTR6 (0.55) | HTR6CHRNB2CHRNA4 | |
| SCHEMBL4573254 | 0.82 | HTR6 (1.00) | HTR6 | |
| SCHEMBL18553756 | 0.81 | HTR6 (0.62) | HTR6CHRNB2CHRNA4HTR1AHTR2A | |
| SCHEMBL4520805 | 0.81 | CHRNB2 (0.55) | HTR6CHRNB2CHRNA4 | |
| SCHEMBL4690981 | 0.76 | HTR6 (0.61) | HTR6CHRNB2CHRNA4HTR1ADRD2 | |
| SCHEMBL20485034 | 0.75 | HTR6 (0.72) | HTR6 | |
| SCHEMBL3826873 | 0.75 | HTR6 (1.00) | HTR6HTR1ADRD2HTR2AHTR7 | |
| SCHEMBL4494776 | 0.74 | HTR6 (0.58) | HTR6 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 20 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1476428-B1 | PYRIDYL SULFONE DERIVATIVES AS 5-HT6 RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2010-11-17 | — | — | EP | claimed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | claimed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | claimed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | claimed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | claimed |
| US-6855709-B2 | Pyridyl sulfone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-02-15 | — | — | US | claimed |
| US-20030186968-A1 | Pyridyl sulfone derivatives | PHARMACIA & UPJOHN COMPANY | 2003-10-02 | — | — | US | claimed |
| EP-1476428-B1 | PYRIDYL SULFONE DERIVATIVES AS 5-HT6 RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| EP-1476428-B1 | PYRIDYL SULFONE DERIVATIVES AS 5-HT6 RECEPTOR LIGANDS | PHARMACIA & UPJOHN CO LLC (US) | 2010-11-17 | — | — | EP | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2010-05-13 | — | — | US | disclosed |
| CN-101500611-A | Combination of a cholinesterase inhibitor and a compound with 5-HT6 receptor affinity | ESTEVE LABOR DR (ES) | 2009-08-05 | — | — | CN | disclosed |
| EP-2040755-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | Laboratorios Del. Dr. Esteve, S.A. (ES) | 2009-04-01 | — | — | EP | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| WO-2007147883-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | LABORATORIOS DEL DR. ESTEVE, S.A. (ES) | 2007-12-27 | — | — | WO | disclosed |
| US-6855709-B2 | Pyridyl sulfone derivatives | PHARMACIA & UPJOHN COMPANY (US) | 2005-02-15 | — | — | US | disclosed |
| EP-1476428-A1 | PYRIDYL SULFONE DERIVATIVES AS 5-HT6 RECEPTOR LIGANDS | PHARMACIA & UPJOHN COMPANY (US) | 2004-11-17 | — | — | EP | disclosed |
| US-20030186968-A1 | Pyridyl sulfone derivatives | PHARMACIA & UPJOHN COMPANY | 2003-10-02 | — | — | US | disclosed |
| WO-2003072548-A1 | PYRIDYL SULFONE DERIVATIVES AS 5-HT RECEPTOR ANTAGONISTS | PHARMACIA & UPJOHN COMPANY (US) | 2003-09-04 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030186968-A1 | Pyridyl sulfone derivatives | HTR6, TPH1, HTR1A | HTR6 1/4885CHRNB2 589/4885CHRNA4 492/4885 |
| US-20100120747-A1 | COMBINATION OF A CHOLINESTERASE INHIBITOR AND A COMPOUND WITH 5-HT6 RECEPTOR AFFINITY | HTR6, AANAT, ACHE | HTR6 1/4885CHRNB2 78/4885CHRNA4 56/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.